Gilead price target raised to $101 from $88 at Mizuho

Mizuho analyst Salim Syed raised the firm’s price target on Gilead Sciences to $101 from $88 and keeps a Buy rating on the shares. In a post-Q4 model update, the analyst increased the firm’s peak sales estimates for Gilead’s HIV business to $20B from $19B.